Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Interferon alpha oral lozenge
Interferon alpha lozenge · 1 trial · 4 indications
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
| Name | Type | Description |
|---|---|---|
| Interferon alpha oral lozenge | DRUG | dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year |
Inclusion Criteria: * The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement. 1. Exclusion of other known causes of interstitial...
Interferon alpha lozenge is an orally administered formulation of interferon alpha developed by Ainos, Inc. under the ticker AIMD. It is being studied in respiratory tract diseases, including interstitial lung diseases such as idiopathic pulmonary fibrosis. The lozenge is a small molecule modality delivered orally rather than by injection.
Interferon alpha lozenge is being studied for respiratory tract diseases, specifically conditions including idiopathic pulmonary fibrosis and other interstitial lung diseases. The only recorded clinical trial enrolled adults aged 50 years and older with idiopathic pulmonary fibrosis. It is investigational and has not been established as a treatment for any condition.
Ainos, Inc., which trades under the ticker AIMD, is the developer of interferon alpha lozenge. The company is advancing the oral interferon alpha formulation as a clinical-stage asset in respiratory indications.
Interferon alpha lozenge is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program remains investigational and is still in clinical development.
Interferon alpha lozenge has been evaluated in one completed Phase 2 trial, NCT01442779, titled Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis. That study enrolled 18 participants in the United States, was uncontrolled, and included adults aged 50 years and older.
Yes, interferon alpha oral lozenge is another name for interferon alpha lozenge. Both names refer to the same Ainos, Inc. oral interferon alpha product candidate being studied in respiratory tract diseases, so readers searching either term are looking at the same asset.